We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+9.8%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.77B
AUM Growth
+$591M
(+27%)
Cap. Flow
+$347M
Cap. Flow
% of AUM
12.51%
Top 10 Holdings %
Top 10 Hldgs %
59.71%
Holding
55
New
19
Increased
10
Reduced
9
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Danaher
DHR
|
+$108M |
| 2 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$105M |
| 3 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
+$84M |
| 4 |
Cardinal Health
CAH
|
+$81.8M |
| 5 |
HOLX
Hologic
HOLX
|
+$74.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$115M |
| 2 |
AET
Aetna Inc
AET
|
+$95.4M |
| 3 |
Merck
MRK
|
+$93.7M |
| 4 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
+$77.9M |
| 5 |
Align Technology
ALGN
|
+$60.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.65% |
| 2 | Financials | 4.93% |
| 3 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BIVV
1
DELISTED
Bioverativ Inc. Common Stock
BIVV
| $390M | 14.06% |
6,475,000
+1,475,000
| +30% | +$84M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $250M | 9.02% |
1,925,000
+525,000
| +38% | +$64.3M |
|
3
Labcorp
LH
$25.9B
| $212M | 7.65% |
1,600,500
+407,400
| +34% | +$49.9M |
|
4
Edwards Lifesciences
EW
$50B
| $142M | 5.12% |
3,600,000
-150,000
| -4% | -$5.48M |
|
|
AET
5
DELISTED
Aetna Inc
AET
| $137M | 4.93% |
900,000
-675,000
| -43% | -$95.4M |
|
|
6
Danaher
DHR
$138B
| $118M | 4.27% |
1,581,840
+1,448,533
| +1,087% | +$108M |
|
7
Neurocrine Biosciences
NBIX
$18.7B
| $117M | 4.23% |
2,550,178
+1,325,178
| +108% | +$64.3M |
|
|
MNK
8
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $108M | 3.88% |
+2,402,350
| New | +$105M |
|
9
Intuitive Surgical
ISRG
$126B
| $95.7M | 3.45% |
920,772
-429,228
| -32% | -$41.3M |
|
10
Pacira BioSciences
PCRX
$1.06B
| $85.6M | 3.09% |
1,793,799
+693,799
| +63% | +$32.2M |
|
|
11
Cardinal Health
CAH
$53.2B
| $84.5M | 3.05% |
+1,084,396
| New | +$81.8M |
|
12
Vertex Pharmaceuticals
VRTX
$122B
| $78.4M | 2.83% |
608,426
-416,574
| -41% | -$50.1M |
|
|
HOLX
13
DELISTED
Hologic
HOLX
| $76.6M | 2.76% |
+1,688,060
| New | +$74.5M |
|
14
Haemonetics
HAE
$3.85B
| $73.2M | 2.64% |
1,854,872
+254,872
| +16% | +$10.5M |
|
15
Sarepta Therapeutics
SRPT
$1.64B
| $68.5M | 2.47% |
2,031,890
+481,890
| +31% | +$15.7M |
|
16
Zimmer Biomet
ZBH
$18.4B
| $65.2M | 2.35% |
+522,653
| New | +$62M |
|
17
Humana
HUM
$44B
| $59.9M | 2.16% |
249,098
+124,098
| +99% | +$28.1M |
|
18
AbbVie
ABBV
$455B
| $58M | 2.09% |
+799,430
| New | +$53.7M |
|
19
Pediatrix Medical
MD
$2.17B
| $56.9M | 2.05% |
+942,730
| New | +$55.9M |
|
|
AGN
20
DELISTED
Allergan plc
AGN
| $50.7M | 1.83% |
+208,700
| New | +$49M |
|
21
Bristol-Myers Squibb
BMY
$132B
| $45.4M | 1.64% |
815,120
+365,120
| +81% | +$19.9M |
|
22
State Street Health Care Select Sector SPDR ETF
XLV
$42.2B
| $37.5M | 1.35% |
+472,780
| New | +$36M |
|
|
CVRS
23
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $37.2M | 1.34% |
19,981,655
| – | – |
|
24
Centene
CNC
$30.1B
| $34.6M | 1.25% |
+865,728
| New | +$32.7M |
|
|
WBA
25
DELISTED
Walgreens Boots Alliance
WBA
| $33.2M | 1.2% |
+424,350
| New | +$34.9M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q2 2017 Portfolio in Review
As of Q2 2017, HealthCor Management held 55 positions worth $2.77B, up 27% from $2.18B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
HealthCor Management deployed $347M of net new capital in Q2 2017, opening 19 new positions and adding to 10 existing holdings. Its largest new stake was MALLINCKRODT PUBLIC LIMITED COMPANY: 2,402,350 shares worth $108M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Financials and Materials.
On the sell side, the largest reduction was Aetna Inc, an estimated $95.4M trimmed.
- HealthCor Management's largest Q2 2017 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 2,402,350 shares worth $108M.
- HealthCor Management added most to Danaher in Q2 2017, an estimated $108M increase.
- HealthCor Management's biggest Q2 2017 reduction was Aetna Inc, cutting an estimated $95.4M.
- HealthCor Management fully exited Alexion Pharmaceuticals in Q2 2017, selling an estimated $115M.
- HealthCor Management's ten largest holdings make up 60% of its $2.77B portfolio in Q2 2017.
- HealthCor Management opened 19 new positions and closed 16 in Q2 2017.
- HealthCor Management's portfolio value rose 27% quarter-over-quarter to $2.77B.
Based on HealthCor Management's 13F filing for Q2 2017, filed 14 Aug 2017.